PL1690549T3 - Środek immunoterapeutyczny do stosowania w połączeniu z innymi lekami do skojarzonego leczenia gruźlicy - Google Patents

Środek immunoterapeutyczny do stosowania w połączeniu z innymi lekami do skojarzonego leczenia gruźlicy

Info

Publication number
PL1690549T3
PL1690549T3 PL04791401T PL04791401T PL1690549T3 PL 1690549 T3 PL1690549 T3 PL 1690549T3 PL 04791401 T PL04791401 T PL 04791401T PL 04791401 T PL04791401 T PL 04791401T PL 1690549 T3 PL1690549 T3 PL 1690549T3
Authority
PL
Poland
Prior art keywords
agent
combined treatment
immunotherapic
pharmaceuticals
tuberculosis
Prior art date
Application number
PL04791401T
Other languages
English (en)
Inventor
Iglesias Pere Joan Cardona
Riera Isabel Amat
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of PL1690549T3 publication Critical patent/PL1690549T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL04791401T 2003-10-31 2004-10-29 Środek immunoterapeutyczny do stosowania w połączeniu z innymi lekami do skojarzonego leczenia gruźlicy PL1690549T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200302551A ES2231037B1 (es) 2003-10-31 2003-10-31 Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
PCT/ES2004/000482 WO2005042013A1 (es) 2003-10-31 2004-10-29 Agente immunoterápico útil para el tratamento combinado de la tuberculosis en associación con otros fármacos
EP04791401A EP1690549B1 (en) 2003-10-31 2004-10-29 Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals

Publications (1)

Publication Number Publication Date
PL1690549T3 true PL1690549T3 (pl) 2010-01-29

Family

ID=34530979

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04791401T PL1690549T3 (pl) 2003-10-31 2004-10-29 Środek immunoterapeutyczny do stosowania w połączeniu z innymi lekami do skojarzonego leczenia gruźlicy

Country Status (21)

Country Link
US (1) US8246944B2 (pl)
EP (1) EP1690549B1 (pl)
JP (1) JP4998988B2 (pl)
KR (1) KR101146469B1 (pl)
CN (1) CN100490894C (pl)
AT (1) ATE428442T1 (pl)
AU (1) AU2004285305B2 (pl)
BR (1) BRPI0415695B8 (pl)
CA (1) CA2543659C (pl)
DE (1) DE602004020663D1 (pl)
DK (1) DK1690549T3 (pl)
ES (2) ES2231037B1 (pl)
HK (1) HK1098362A1 (pl)
IL (1) IL175030A (pl)
MA (1) MA28121A1 (pl)
NZ (1) NZ546715A (pl)
PL (1) PL1690549T3 (pl)
PT (1) PT1690549E (pl)
RU (1) RU2341287C2 (pl)
WO (1) WO2005042013A1 (pl)
ZA (1) ZA200604234B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
EP2027865A4 (en) * 2006-05-12 2010-08-18 Univ Hokkaido Nat Univ Corp LIPOSOME HAVING A LIPIDIC MEMBRANE CONTAINING A BACTERIAL CELLULAR COMPONENT
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2471511A1 (en) 2011-01-04 2012-07-04 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
WO2012093137A1 (en) * 2011-01-04 2012-07-12 Archivel Farma, Sl Liposome formulation suitable for treating or preventing tuberculosis
EP2802345B1 (en) 2012-01-12 2018-03-07 Archivel Farma, S.l. Mtb-c vaccine against allergic responses
ES2758400B2 (es) 2018-11-02 2021-01-20 Univ Granada Nanoparticulas biomimeticas mediadas por mamc
WO2023062066A1 (en) 2021-10-14 2023-04-20 Archivel Farma, S.L. Liposome formulations for treatment of active tuberculosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3125598A1 (de) * 1981-06-30 1983-01-13 Mahle Gmbh, 7000 Stuttgart Einrichtung zur druckbeaufschlagung des presszylinders einer druckgiessmaschine
JPS59161320A (ja) * 1983-03-04 1984-09-12 Maruyama Chisato リポ多糖体およびその製造法
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
JPS624701A (ja) * 1985-06-29 1987-01-10 Maruyama Chisato リポ多糖体及びその製造法
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
CA2346218A1 (en) * 1998-10-08 2000-04-20 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
RU2153354C1 (ru) * 1999-03-31 2000-07-27 Московский городской научно-практический центр борьбы с туберкулезом Вакцина против туберкулеза
AU2002239485A1 (en) * 2000-12-08 2002-06-18 The Johns Hopkins University Methods for improved diagnosis and treatment of mycobacterial infections
JP3944452B2 (ja) * 2001-01-08 2007-07-11 アメリカ合衆国 潜伏性ヒト結核モデル、診断用抗原、および使用法
EP1379529A2 (en) * 2001-03-16 2004-01-14 Sarawak Medichem Pharmaceuticals, Inc. Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
WO2003018053A1 (en) 2001-08-22 2003-03-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine against mycobacterial-induced diseases
CA2474794A1 (en) 2002-01-29 2003-08-07 Modi, Rajiv Indravadan Method of providing prophylaxis for tuberculosis in hiv positive individuals
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
DE102004053141A1 (de) * 2004-11-03 2006-05-04 Schülke & Mayr GmbH Desinfektionsmittel mit verbesserter Wirksamkeit gegen Mykobakterien

Also Published As

Publication number Publication date
RU2341287C2 (ru) 2008-12-20
JP4998988B2 (ja) 2012-08-15
KR20060126963A (ko) 2006-12-11
CN1874785A (zh) 2006-12-06
IL175030A (en) 2012-02-29
AU2004285305A1 (en) 2005-05-12
CA2543659A1 (en) 2005-05-12
ES2325835T3 (es) 2009-09-21
ATE428442T1 (de) 2009-05-15
ZA200604234B (en) 2007-11-28
DE602004020663D1 (de) 2009-05-28
DK1690549T3 (da) 2009-08-17
EP1690549A1 (en) 2006-08-16
ES2231037A1 (es) 2005-05-01
ES2231037B1 (es) 2005-12-16
EP1690549B1 (en) 2009-04-15
KR101146469B1 (ko) 2012-05-21
JP2007509910A (ja) 2007-04-19
HK1098362A1 (en) 2007-07-20
AU2004285305B2 (en) 2009-11-12
RU2006118795A (ru) 2007-12-10
PT1690549E (pt) 2009-07-20
NZ546715A (en) 2008-05-30
US8246944B2 (en) 2012-08-21
BRPI0415695A (pt) 2006-12-26
MA28121A1 (fr) 2006-08-01
CN100490894C (zh) 2009-05-27
US20070269501A1 (en) 2007-11-22
BRPI0415695B1 (pt) 2019-09-10
WO2005042013A1 (es) 2005-05-12
BRPI0415695A8 (pt) 2019-01-15
CA2543659C (en) 2012-04-17
BRPI0415695B8 (pt) 2021-05-25
IL175030A0 (en) 2006-08-20

Similar Documents

Publication Publication Date Title
HK1098362A1 (en) Immunotherapic agent which is used for the combined treatment of tuberculosis togetheir with other pharmaceuticals
TW200508214A (en) Novel compounds
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
EP1611880A3 (en) Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction
YU20050003A (sh) Postupak i uređaj za davanje co
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
IL171683A (en) Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment
WO2004006858A3 (en) Compounds, compositions, and methods employing same
ATE342053T1 (de) Formulierungen zur inhalation
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
WO2002030405A3 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
GR1004358B (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
IL165213A0 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilizationmedicament or diagnostic agent and medicament containing same
MXPA04005552A (es) Analogos de vitamina d.
WO2003039592A3 (de) Zelluläre impfstoffe mit adjuvanzien
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
IL168307A (en) Compositions containing roflumilast and (r,r)-formoterol
WO2003039457A3 (en) Anti-mycobacterial compounds
GB0128071D0 (en) Medicament
WO2003059380A3 (de) Orale vakzinierung
WO2002094184A3 (en) Vaccines for the treatment of autoimmune disease